Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 199

1.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

PMID:
29863955
2.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.

von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, Anderson M, McCall B, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Reck M.

Oncologist. 2018 Jun;23(6):654-e58. doi: 10.1634/theoncologist.2017-0690. Epub 2018 Feb 7.

PMID:
29438092
3.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

4.

[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].

Qin YY, Zhang DH, Lin XQ, Ouyang M, Zhang JX, Xie ZH, Liu YQ, Li SY, Zhou CZ.

Zhonghua Zhong Liu Za Zhi. 2017 Nov 23;39(11):855-861. doi: 10.3760/cma.j.issn.0253-3766.2017.11.009. Chinese.

PMID:
29151293
5.

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.

Eur J Cancer. 2017 Nov;86:186-196. doi: 10.1016/j.ejca.2017.08.027. Epub 2017 Oct 6.

PMID:
28992562
6.

Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).

Argiris A, Lee JW, Stevenson J, Sulecki MG, Hugec V, Choong NW, Saltzman JN, Song W, Hansen RM, Evans TL, Ramalingam SS, Schiller JH.

Ann Oncol. 2017 Dec 1;28(12):3037-3043. doi: 10.1093/annonc/mdx534.

PMID:
28950351
7.

Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin-Paclitaxel: A Prospective Study.

Otsuka T, Nojiri T, Minami S, Hosoda H, Kuroyama M, Hirata H, Nakanishi K, Yamamoto S, Komuta K, Kangawa K, Kijima T.

Anticancer Res. 2017 Jul;37(7):3505-3512.

PMID:
28668839
8.

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, Carbone DP.

PLoS One. 2017 Jun 23;12(6):e0178420. doi: 10.1371/journal.pone.0178420. eCollection 2017.

9.

The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer.

Usmanij EA, Natroshvili T, Timmer-Bonte JNH, Oyen WJG, van der Drift MA, Bussink J, Geus-Oei LF.

J Nucl Med. 2017 Aug;58(8):1243-1248. doi: 10.2967/jnumed.116.185314. Epub 2017 Mar 23.

PMID:
28336778
10.

Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.

Yoh K, Goto Y, Naito Y, Kishi K, Mori K, Hotta K, Hosomi Y, Yamada K, Tanai C, Tomizawa Y, Inoue A, Hasegawa Y, Nishio M, Ohashi Y, Kunitoh H.

Anticancer Res. 2017 Mar;37(3):1507-1513.

PMID:
28314326
11.

Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer.

Yamasaki M, Murakami I, Nakano K, Doi M, Kitaguchi S, Kondo T, Sakurai J, Hattori N, Arita KI.

Anticancer Res. 2017 Feb;37(2):923-928.

PMID:
28179353
12.

A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

Miura S, Maemondo M, Iwashima A, Harada T, Sugawara S, Kobayashi K, Inoue A, Nakagawa T, Takiguchi Y, Watanabe H, Ishida T, Terada M, Kagamu H, Gemma A, Yoshizawa H.

Invest New Drugs. 2017 Apr;35(2):227-234. doi: 10.1007/s10637-017-0436-1. Epub 2017 Feb 1.

PMID:
28150074
13.

Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.

Spence MM, Hui RL, Chang JT, Schottinger JE, Millares M, Rashid N.

J Manag Care Spec Pharm. 2017 Feb;23(2):195-205. doi: 10.18553/jmcp.2017.23.2.195.

14.

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.

González García J, Gutiérrez Nicolás F, Nazco Casariego GJ, Valcárcel Nazco C, Batista López JN, Oramas Rodríguez J.

Farm Hosp. 2017 Jan 1;41(n01):3-13. doi: 10.7399/fh.2017.41.1.10142.

15.

Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.

Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S.

Clin Lung Cancer. 2017 Jan;18(1):50-59. doi: 10.1016/j.cllc.2016.09.013. Epub 2016 Oct 19.

PMID:
27856142
16.

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

Kanda S, Goto K, Shiraishi H, Kubo E, Tanaka A, Utsumi H, Sunami K, Kitazono S, Mizugaki H, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Hozumi H, Tamura T.

Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.

17.

Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.

Menter AR, Carroll NM, Sakoda LC, Delate T, Hornbrook MC, Jain RK, Kushi LH, Quinn VP, Ritzwoller DP.

Clin Lung Cancer. 2017 Mar;18(2):189-197.e3. doi: 10.1016/j.cllc.2016.07.008. Epub 2016 Aug 20.

18.

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.

de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):8-16. Epub 2016 Sep 6.

19.

Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.

Gilden DM, Kubisiak JM, Pohl GM, Ball DE, Gilden DE, John WJ, Wetmore S, Winfree KB.

J Med Econ. 2017 Feb;20(2):151-161. doi: 10.1080/13696998.2016.1230550. Epub 2016 Sep 14.

PMID:
27574722
20.

Targeted Therapies for Lung Cancer.

Stinchcombe TE.

Cancer Treat Res. 2016;170:165-82. doi: 10.1007/978-3-319-40389-2_8. Review.

PMID:
27535394

Supplemental Content

Loading ...
Support Center